The Crohn’s & Colitis Foundation released the following statement today after the New York State Senate passed the Crohn’s & Colitis Fairness Act (S3295).
The Crohn’s & Colitis Foundation (the Foundation) is pleased to announce seven new members of its National Board of Trustees, which oversees the management of the organization’s policies, practices, principles, affairs, funds, and property.
The Crohn’s & Colitis Foundation (the Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., announced today a partnership to develop a program to jumpstart advances in the area of shared decision-making in inflammatory bowel diseases (IBD). The program aims to identify gaps in effective communication and the lack of research on how providers and patients can make decisions together and prevent suboptimal treatment.
The Crohn’s & Colitis Foundation, the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD), and ReachMD®, the nation’s largest medical education learning platform for healthcare professionals, have partnered to deliver exclusive content to ReachMD learners.
The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) announced today that they are partnering to co-sponsor the first-ever “Crohn’s & Colitis Congress,” which will take place in Las Vegas in January 2018.
Researchers have successfully identified biological signatures in pediatric patients with newly diagnosed Crohn’s disease (CD) capable of predicting whether a child will develop disease-related complications requiring major surgery within three to five years. The results of this research, “Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study,” have been published today in the high impact factor journal, The Lancet.
For the past 50 years, the Crohn’s & Colitis Foundation of America has worked to improve the lives of patients living with Crohn’s disease and ulcerative colitis, and to find cures for these debilitating digestive diseases. Today, the Foundation unveiled its new brand, which includes a new brand message, “uniting to care and cure,” and a new logo with a unifying symbol reflecting the organization’s commitment to the IBD community. In addition, the Foundation has amended its name to the Crohn’s & Colitis Foundation to place greater emphasis on its mission to cure these debilitating digestive diseases.